Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme

Eryilmaz, Melek; Mutlu, HASAN; Musri, Fatma; Salim, Derya; Tazegul, GÖKHAN; COŞKUN, HASAN

doi:10.1177/1078155216643858

Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme

Eryilmaz M. K., Mutlu H., Musri F. Y., Salim D. K., Tazegul G., COŞKUN H. Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.23, sa.5, ss.392-395, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23 Sayı: 5
Basım Tarihi: 2017
Doi Numarası: 10.1177/1078155216643858
Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.392-395
Anahtar Kelimeler: Bevacizumab, bleeding, recurrent glioblastome multiforme, COMPLICATIONS, TEMOZOLOMIDE, THERAPY, GLIOMAS
Akdeniz Üniversitesi Adresli: Evet

Özet

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor, and it has been shown to improve progression-free survival in patients with recurrent glioblastome multiforme when administered as second-line therapy. However, it has been associated with serious and fatal hemorrhagic events. Here, we present a 68-year-old male who developed severe periocular bleeding while on bevacizumab for recurrent temozolamide-resistant glioblastome multiforme.